Feedback
Settings

Settings

Goto Application

1. ES2760510 - Derivado de benzofurano, método de preparación del mismo y uso del mismo en medicina

PermaLink
Office
Spain
Application Number 16865671
Application Date 02.11.2016
Publication Number 2760510
Publication Date 14.05.2020
Publication Kind T3
IPC
C07D 405/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
A61K 31/4545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/4433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4433containing a six-membered ring with oxygen as a ring hetero atom
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/4433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4433containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 405/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Applicants Jiangsu Hengrui Medicine Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd.
Inventors LU, Biao
SHEN, Xiaodong
HE, Mingxun
LIU, Dong
ZHANG, Minsheng
Agents Isern Jara Jorge
Priority Data 201510800975 19.11.2015 CN
Title
(ES) Derivado de benzofurano, método de preparación del mismo y uso del mismo en medicina
Abstract
(ES) Un compuesto de Fórmula (I):**Fórmula** o un tautómero, mesómero, racemato, enantiómero, diastereómero, o mezcla de los mismos, o una sal farmacéuticamente aceptable de los mismos, en donde: el anillo A se selecciona entre el grupo que consiste en heterociclilo y cicloalquilo; cada R1 es idéntico o diferente y se selecciona cada uno independientemente entre el grupo que consiste en hidrógeno, halógeno, alquilo, haloalquilo, alcoxi, haloalcoxi, amino, nitro, hidroxi, ciano, cicloalquilo, heterociclilo, arilo, heteroarilo, -OR6, -C(O)R6, -C(O)OR6, - S(O)mR6, -S(O)mNR7R8 y -(CH2)xRa, en donde el alquilo, haloalquilo, heterociclilo, arilo y heteroarilo está cada uno independiente y opcionalmente sustituido con uno o más grupos seleccionados entre el grupo que consiste en alquilo, haloalquilo, halógeno, amino, nitro, ciano, hidroxi, alcoxi, haloalcoxi, hidroxialquilo, cicloalquilo, heterociclilo, arilo y heteroarilo; Ra se selecciona del grupo que consiste en halógeno, cicloalquilo, heterociclilo y -NR7R8, en donde el cicloalquilo y heterociclilo está cada uno independiente y opcionalmente sustituido con uno o más grupos seleccionados entre el grupo que consiste en alquilo, haloalquilo, halógeno, amino, nitro, ciano, hidroxi, alcoxi, haloalcoxi, hidroxialquilo, cicloalquilo, heterociclilo, arilo y heteroarilo; R2 es hidrógeno o alquilo, en donde el alquilo está opcionalmente sustituido con uno o más grupos seleccionados entre el grupo que consiste en halógeno, hidroxi, ciano, cicloalquilo y heterociclilo; R3 se selecciona entre el grupo que consiste en hidrógeno, alquilo, halógeno, ciano, alcoxi y haloalquilo; cada R4 es idéntico o diferente y se selecciona cada uno independientemente entre el grupo que consiste en hidrógeno, alquilo, haloalquilo, hidroxi, amino, alcoxi, haloalcoxi, cicloalquilo, heterociclilo, arilo, heteroarilo, -OR6, -C(O)R6, -C(O)OR6, -S(O)mR6, -S(O)mNR7R8 y -NR7R8; cada R5 es idéntico o diferente y se selecciona cada uno independientemente entre el grupo que consiste en hidrógeno, alquilo, oxo, halógeno, haloalquilo, hidroxi, amino, alcoxi, haloalcoxi, cicloalquilo, heterociclilo, arilo, heteroarilo, -OR6, -C(O)R6, -C(O)OR6, -S(O)mR6, -S(O)mNR7R8 y -NR7R8; R6 se selecciona entre el grupo que consiste en hidrógeno, alquilo, haloalquilo, alcoxi, hidroxialquilo, hidroxi, amino, cicloalquilo, heterociclilo, arilo y heteroarilo; R7 y R8 son idénticos o diferentes y se selecciona cada uno independientemente entre el grupo que consiste en hidrógeno, alquilo, alcoxi, hidroxialquilo, hidroxi, amino, alcoxicarbonilo, cicloalquilo, heterociclilo, arilo y heteroarilo, en donde el alquilo, amino, cicloalquilo, heterociclilo, arilo y heteroarilo está cada uno independiente y opcionalmente sustituido con uno o más grupos seleccionados entre el grupo que consiste en alquilo, halógeno, hidroxi, amino, alcoxicarbonilo, nitro, ciano, alcoxi, hidroxialquilo, cicloalquilo, heterociclilo, arilo y heteroarilo; m es 0, 1 o 2; n es 0, 1, 2 o 3; p es 0, 1, 2, 3, 4 o 5; q es 0, 1 o 2; y x es 0, 1, 2 o 3.
Related patent documents
PT3378859
LT3378859
CN107428742
AU2016357900
KR1020180081587
EP3378859
US20180327394
BR112018007876
JP2018538257
RU0002727198
DK3378859
RS59763
WO/2017/084494
PL3378859
CA3002436
MX2018005019
US20200354349
# -